Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

• Published in: The New England journal of medicine Vol. 329; no. 17; pp. 1219 - 1224
• Main Authors: Press, Oliver W, Eary, Janet F, Appelbaum, Frederick R, Martin, Paul J, Badger, Christopher C, Nelp, Wil B, Glenn, Stephan, Butchko, Greg, Fisher, Darrell, Fisher, Lloyd D, Porter, Bruce, Matthews, Dana C, Bernstein, Irwin D
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 21.10.1993
• Subjects: Antibodies, Monoclonal; Antigens; Antigens, CD - immunology; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte - immunology; Antigens, Neoplasm; Autografts; B-cell lymphoma; Biological and medical sciences; Biopsy; Body weight; Bone marrow; Bone Marrow Transplantation; Cancer therapies; CD20 antigen; Combined Modality Therapy; Dosimetry; Glycoproteins - immunology; Hematologic and hematopoietic diseases; Humans; Immunoglobulins; Immunotherapy; Iodine; Iodine Radioisotopes - administration & dosage; Iodine Radioisotopes - adverse effects; Iodine Radioisotopes - pharmacokinetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Liver; Lymphocytes B; Lymphoma; Lymphoma, B-Cell - metabolism; Lymphoma, B-Cell - physiopathology; Lymphoma, B-Cell - radiotherapy; Lymphoma, B-Cell - therapy; Medical imaging; Medical sciences; Middle Aged; Monoclonal antibodies; Myelosuppression; Nausea; Neutrophils; Radioimmunotherapy; Remission; Remission Induction; Spleen - physiopathology; Studies; Surface antigens; Tetraspanins; Toxicity; Transplantation, Autologous; Tumors; Human; Treatment; Antibody; Lymphoproliferative syndrome; Phase I trial; Immunoradiotherapy; Malignant hemopathy; B-Lymphocyte; Lymphoma
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199310213291702

Treatment with anthracycline-based chemotherapy regimens results in complete remission in 50 to 90 percent of patients with intermediate and high-grade non-Hodgkin's lymphoma and long-term disease-free survival in 30 to 60 percent. Unfortunately, few patients with low-grade lymphoma or relapses of any type of lymphoma can be cured with conventional approaches 1 . High-dose chemoradiotherapy with bone marrow transplantation cures 10 to 50 percent of patients with lymphoma in relapse, but 40 to 80 percent relapse again and 5 to 20 percent die of complications related to transplantation 2 , 3 . The use of larger doses of chemoradiotherapy has not been feasible because . . .